Search Within

Neil Jayendra Shah

Formats
  1. Meeting Abstract (56)
  2. Journal Article (32)
  3. Conference Paper (1)
  4. Editorial (1)
  5. Research Letter (1)
Groups
  1. Department of Medicine (91)
  2. Genitourinary Oncology Service (91)
  3. Solid Tumor Oncology Division (91)
  4. Hematologic Malignancies, Division of (36)
  5. Weinberg Fellows (35)
  6. Population Sciences Research Program (28)

More Groups

People
  1. Robert Motzer (39)
  2. Martin Voss (28)
  3. Ritesh Kotecha (28)
  4. Maria Carlo (24)
  5. Darren Feldman (22)
  6. David Aggen (22)

More People

Years
  1. 2025 (16)
  2. 2024 (19)
  3. 2023 (22)
  4. 2022 (18)
  5. 2021 (13)
  6. 2020 (2)

More Years

Publications
  1. Journal of Clinical Oncology (47)
  2. Journal for ImmunoTherapy of Cancer (7)
  3. Cancers (4)
  4. The Oncologist (4)
  5. Annals of Oncology (2)
  6. Cancer (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (49)
  2. Oxford University Press (8)
  3. Biomed Central Ltd (7)
  4. MDPI (5)
  5. American Association for Cancer Research (3)
  6. Elsevier BV (3)

More Publishers

Results (91)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The impact of immunosuppressive agents on immune checkpoint inhibitor efficacy in patients with advanced melanoma: A real-world, multicenter, retrospective study
    Journal Article

    Lev-Ari, S.; Serzan, M.; Wu, T.; Ip, A.; Pascual, L.; Sinclaire, B.; Adams, S.; Marafelias, M.; Ayyagari, L.; Gill, S. K.; more...
    Cancer (2023)

    Fulltext@MSK | Save
  • Progression-free survival after second line of therapy for metastatic clear cell renal cell carcinoma in patients treated with first-line immunotherapy combinations
    Research Letter

    Fitzgerald, K. N.; Duzgol, C.; Knezevic, A.; Shapnik, N.; Kotecha, R.; Aggen, D. H.; Carlo, M. I.; Shah, N. J.; Voss, M. H.; Feldman, D. R.; more...
    European Urology (2023)

    Fulltext@MSK | Save
  • Impact of sarcomatoid features on treatment outcomes in metastatic clear cell renal cell carcinoma treated with first-line immunotherapy combinations
    Meeting Abstract

    Fitzgerald, K. N.; Duzgol, C.; Knezevic, A.; Shapnik, N.; Kotecha, R. R.; Aggen, D. H.; Carlo, M. I.; Shah, N. J.; Voss, M. H.; Feldman, D. R.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Correlating HLA variants and the emergence of immune-related adverse events (irAEs) from ipilimumab/nivolumab (I/N) in patients (pts) treated on CheckMate 214
    Meeting Abstract

    Voss, M. H.; Shah, N. J.; Kalvin, H. L.; Lihm, J.; Li, H.; Kotecha, R. R.; Jarchum, I.; Vemula, S. V.; Gupta, S.; Motzer, R. J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Shah, N. J.; Campbell, M. T.; Mao, S. S.; Ornstein, M. C.; Haas, N. B.; Gao, X.; Hammers, H. J.; Keshava-Prasad, H.; Yan, H.; Esquibel, V.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Dermatologic immune-related adverse events to checkpoint inhibitors in cancer
    Editorial

    Shah, N. J.; Lacouture, M. E.
    Journal of Allergy and Clinical Immunology (2023)

    Fulltext@MSK | Save
  • Real-world treatment patterns and clinical outcomes for metastatic renal cell carcinoma in the current treatment era
    Journal Article

    Shah, N. J.; Sura, S. D.; Shinde, R.; Shi, J.; Singhal, P. K.; Robert, N. J.; Vogelzang, N. J.; Perini, R. F.; Motzer, R. J.
    European Urology Open Science (2023)

    Fulltext@MSK | Save
  • Matched molecular profiling of cell-free DNA and tumor tissue in patients with advanced clear cell renal cell carcinoma
    Journal Article

    Kotecha, R. R.; Gedvilaite, E.; Ptashkin, R.; Knezevic, A.; Murray, S.; Johnson, I.; Shapnik, N.; Feldman, D. R.; Carlo, M. I.; Shah, N. J.; more...
    JCO Precision Oncology (2022)

    Fulltext@MSK | Save
  • Prediction of best response for NSCLC patients receiving immunotherapy by machine learning models
    Meeting Abstract

    Zhang, Y.; Gupta, S.; Belouali, A.; Lev-Ari, S.; Shah, N.; Krishnamurthy, K.; Serzan, M.; Alaoui, A.; McGarvey, P.; Atkins, M.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • A multicohort phase 1b study (STELLAR-002) of XL092 in combination with immunotherapy in patients with advanced solid tumors
    Meeting Abstract

    McGregor, B.; Choueiri, T.; Shah, N.; Bajaj, A.; Chahoud, J.; O'Neil, B.; Michalski, J.; Garmezy, B.; Jin, L.; Aziz, U.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save